NCT01190306

Brief Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL), when used to treat keratoconus.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
127

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Aug 2010

Shorter than P25 for phase_3

Geographic Reach
1 country

9 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

August 25, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 27, 2010

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

March 4, 2013

Completed
Last Updated

July 12, 2022

Status Verified

July 1, 2022

Enrollment Period

1.3 years

First QC Date

August 25, 2010

Results QC Date

December 13, 2012

Last Update Submit

July 5, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Corneal Curvature.

    6 Months

Study Arms (2)

CXL Treatment

EXPERIMENTAL

Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.

Device: The VEGA UV-A Illumination SystemDrug: Riboflavin

Sham Control

ACTIVE COMPARATOR

Eyes in the control group will be treated with riboflavin only.

Drug: Riboflavin

Interventions

This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area

CXL Treatment

Riboflavin is a solution that will be delivered to the treatment area

CXL TreatmentSham Control

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older
  • Having a diagnosis of keratoconus
  • Presence of central or inferior steepening
  • Topography consistent with keratoconus
  • Presence of one or more slit lamp or retinoscopy findings associated with keratoconus
  • Contact lens wearers only:Removal of contact lenses for the required period of time
  • Signed written informed consent
  • Willingness and ability to comply with schedule for follow-up visits

You may not qualify if:

  • For keratoconus, a history of previous corneal surgery or the insertion of Intacs in the eye to be treated
  • Corneal pachymetry ≤ 400 microns
  • Previous ocular condition that may predispose the eye for future complications or prevent the possibility of improved vision
  • A history of chemical injury or delayed epithelial healing in the eye(s) to be treated.
  • Pregnancy (including plan to become pregnant) or lactation during the course of the study
  • A known sensitivity to study medications
  • Nystagmus or any other condition that would prevent a steady gaze during the cross-linking treatment or other diagnostic tests
  • A condition that, in the investigator's opinion, would interfere with or prolong epithelial healing.
  • Presence or history of any other condition or finding that, in the investigator's opinion, makes the patient unsuitable as a candidate for cross-linking or study participation or may confound the outcome of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Barnet Dulaney Perkins Eye Center

Phoenix, Arizona, 85016, United States

Location

Woolfson Eye Institute

Atlanta, Georgia, 30328, United States

Location

Minnesota Eye Consultants

Bloomington, Minnesota, 55431, United States

Location

Pamel Vision & Laser Group

New York, New York, 10021, United States

Location

Mt. Sinai Hospital

New York, New York, 10029, United States

Location

OSU Department of Ophthalmoloty

Columbus, Ohio, 43212, United States

Location

Revision Advanced Laser Eye Center

Columbus, Ohio, 43240, United States

Location

Dell Laser Consultants

Austin, Texas, 78746, United States

Location

Slade & Baker Vision Center

Houston, Texas, 77027, United States

Location

MeSH Terms

Conditions

Keratoconus

Interventions

Riboflavin

Condition Hierarchy (Ancestors)

Corneal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

FlavinsPteridinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsHeterocyclic Compounds, 3-RingCoenzymesEnzymes and CoenzymesPigments, BiologicalBiological Factors

Results Point of Contact

Title
Robert Gibson
Organization
Topcon Medical Systems

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 25, 2010

First Posted

August 27, 2010

Study Start

August 1, 2010

Primary Completion

December 1, 2011

Study Completion

December 1, 2011

Last Updated

July 12, 2022

Results First Posted

March 4, 2013

Record last verified: 2022-07

Locations